WASHINGTON, DC (June 30, 2025) – The Association for Accessible Medicines today commented on the announcement by Hikma Pharmaceuticals USA to invest $1 billion to expand its domestic manufacturing and research and development.
“Hikma’s commitment to increase domestic R&D and manufacturing shows the value and commitment AAM members bring to the heath care ecosystem in the U.S.,” said John Murphy III, President and CEO of AAM. “AAM and our members are working closely with the Administration and Congress to foster domestic manufacturing and a more resilient and reliable generic medicines supply.”
Hikma will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey. On Saturday, Hikma broke ground to expand the company’s manufacturing and R&D facility in Columbus, Ohio. They were joined by U.S. Representatives Mike Carey (OH-15) who represents the Columbus area and Buddy Carter (GA-01) who chairs the House Energy and Commerce Health Subcommittee.
Hikma has invested more than $4 billion over the past 15 years to build, enhance, and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of more than 800 medicines.
For media inquiries, contact media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
